Age ≥18 years at the time of signing informed consent.
Have a documented diagnosis of HAE-1/HAE-2 (Type I or II)
Experience ≥1 Investigator-confirmed HAE attack in the first 4 weeks of Screening or ≥2 Investigator-confirmed HAE attacks in 8 weeks of Screening
Able to use at least one acute therapy to treat HAE attacks (such as a plasma-derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)
You may not be if
Concurrent diagnosis of another form of recurrent angioedema (such as acquired angioedema, HAE with normal C1-INH (previously known as HAE Type III), idiopathic angioedema, or recurrent angioedema associated with urticaria).
Any clinically significant renal disease
Any clinically significant hepatic disease
Have used any of the following for long-term prevention of HAE attacks:
1. C1-INH agent (CINRYZE, HAEGARDA, RUCONEST) within 2 weeks prior to Screening.
2. Berotralstat (ORLADEYO) within 3 weeks prior to Screening.
3. Lanadelumab (TAKHZYRO) within 8 weeks prior to the Screening.
4. Androgen use within 12 weeks prior to Screening.
Received prior treatment with any RNA/DNA-based therapy for HAE or intolerant to any prior RNA/DNA-based therapy for any condition, excluding vaccines.
